PR BHFT 0715 - Compounded mAbs - Cancer Therapies (replaces BHFT 0342)
Details
- Published
- 7 May 2026
- Submission
- 22 June 2026
- Source
- uk:atamis:dhsc
Tender description
Supply of Compounded Monoclonal Antibodies. Ranked framework split into 2 Lots as follows: Lot 1- High Volume Products - 5 molecules / all brands Pembrolizumab Rituximab Bevacizumab Daratumumab Nivolumab Lot 2 - Lower Volume Products - 14 molecules / all brands Pertuzumab/trastuzumab Brentuximab Cetuximab Atezolizumab Cemiplimab Avelumab Panitumumab Obinutuzumab Pertuzumab Trastuzumab Ipilimumab Isatuximab Polatuzumab
Timeline
- Completed: Tender published7 May 2026Current notice
- Completed: Submission date22 June 2026
About the buyer
Berkshire Healthcare NHS Foundation Trust is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@berkshire-healthcare-nhs-foundation-trust.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@berkshire-healthcare-nhs-foundation-trust.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@berkshire-healthcare-nhs-foundation-trust.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@berkshire-healthcare-nhs-foundation-trust.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@berkshire-healthcare-nhs-foundation-trust.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@berkshire-healthcare-nhs-foundation-trust.gov |
Related buyers
Buyers similar to Berkshire Healthcare NHS Foundation Trust.
- 514£239.2m
- 381£5.3bn
- 262£44.9m
- 244£140.9m
- 231£25.7m
- 229£225.2m
- 220£11.8m
- 209£131.5m
- 178£11.5bn
- 178£46.5m
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.
